Research programme: soluble epoxide hydrolase inhibitors - Arete Therapeutics

Drug Profile

Research programme: soluble epoxide hydrolase inhibitors - Arete Therapeutics

Alternative Names: AR 9273

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arete Therapeutics
  • Class
  • Mechanism of Action Epoxide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hypertension; Obesity

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hypertension in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA (PO)
  • 17 May 2008 Pharmacodynamics data from a preclinical trial in a model of diet-induced obesity presented at the 23rd Annual Scientific Meeting of the American Society of Hypertension (ASH-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top